Plain-English translation of NCT02332668 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a medication called , an immunotherapy drug that helps the body's immune system fight cancer. Researchers want to see if different doses of this medication can shrink or eliminate advanced cancers in children and teenagers that have either spread through the body, come back after treatment, or did not respond to previous treatments.
Many children with advanced melanoma and other cancers have limited treatment options when standard therapies stop working or fail from the start. This medication works differently than traditional cancer treatments by activating the immune system, and researchers hope it could offer a new path forward for these children.
You likely qualify if…
You likely don't qualify if…
If enrolled, you would receive the medication as an intravenous infusion (through a vein) once every 3 weeks, starting with a dose based on your body weight, with a maximum dose of 200 mg. You would visit the clinic regularly for infusions, blood tests, and scans to monitor how your cancer is responding. The trial is still actively recruiting participants, though enrollment has closed for some cancer types and age groups.
AI-generated summary from trial data · Jul 17, 2026 · Not medical advice
United States